Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, double-blind, placebo-controlled trial

Article Abstract:

Testosterone treatment may increase lean body mass and improve the quality of life of testosterone-deficient HIV-infected men with wasting syndrome. Wasting syndrome is the loss of body weight and muscle mass, which can be significantly debilitating. Researchers assigned 51 HIV-positive men with wasting and low testosterone to regular testosterone or placebo injections for six months. Men who were given testosterone gained 2.4 kilograms of muscle mass, while men given the placebo lost 0.8 kilograms. Hormone-treated men reported improved quality of life and appearance.

Complications and side effects, HIV infection, Drug therapy, HIV infections, Testosterone, Wasting syndrome

---

Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled trial

Article Abstract:

Growth hormone replacement therapy appears to have a positive effect on bone growth in adult men with growth hormone deficiencies. Thirty-two men who developed a growth hormone deficiency in their adult life took either growth hormone or placebo for 18 months. Periodic measurements of bone mineral density, bone turnover, and lean body mass were significantly higher in the group taking growth hormone than those taking placebo. Body fat measurements were lower in the growth hormone group. There were no major side effects reported with growth hormone therapy.

Care and treatment, Bones, Bone density, Growth disorders

---

Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency

Article Abstract:

Growth hormone may reduce some cardiovascular risk factors in people with growth hormone deficiency. In a study of 40 men with adult-onset growth hormone deficiency, growth hormone or placebo was given for 18 months. Growth hormone caused a decrease in blood levels of proteins involved in inflammation, including C-reactive protein and interleukin-6. It also reduced body fat. There is evidence that inflammation plays a role in coronary artery disease so these changes may be beneficial.

Cardiovascular diseases, Risk factors, Physiological aspects, Inflammation, Inflammation mediators

Similar abstracts:

• Abstracts: An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue
• Abstracts: Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial
• Abstracts: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
• Abstracts: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial
• Abstracts: The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: A randomized controlled trial

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.